Back To Search Instructions
13 protocols meet the specified criteria
Disease Site: Melanoma, skin
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0600000101Sentinel Lymph Node Working Group Data Acquisition ProjectOpen
0800000610Tracking Suspicious Skin LesionsOpen
1200000229Skin Cancer Prevention Program BiorepositoryOpen
1200000549A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of RecurrenceOpen
1200000706An open-label, multicenter, Phase II study of continuous oral vemurafenib in patients with locally-advanced, unresectable, stage IIIC or metastatic melanoma and activating exon 15 BRAF mutation other than V600EOpen
1300000016A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma Open
1300000145A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive MelanomaOpen
1300000218A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resectionOpen
1300000305A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV MelanomaOpen
1300000635Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic MelanomaOpen
1404276612Decision Model to Assess Clinico-Pathologic Characteristics Associated with Lymph Node Involvement in MelanomaOpen
R0306Non-Steroidal Anti-Inflammatory Drugs and Melanoma-- A Pooling StudyOpen